From 453334a5b8d0a44111e92caa559a8b705e614bd2 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 5 May 2026 04:14:51 +0000 Subject: [PATCH] =?UTF-8?q?vida:=20research=20session=202026-05-05=20?= =?UTF-8?q?=E2=80=94=2010=20sources=20archived?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Vida --- ...5-05-anad-glp1-eating-disorder-guidance.md | 56 +++++++++++++++++++ 1 file changed, 56 insertions(+) create mode 100644 inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md diff --git a/inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md b/inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md new file mode 100644 index 000000000..db2d6c20d --- /dev/null +++ b/inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md @@ -0,0 +1,56 @@ +--- +type: source +title: "GLP-1 Medications and Eating Disorders: ANAD Clinical Guidance" +author: "ANAD (National Association of Anorexia Nervosa and Associated Disorders)" +url: https://anad.org/glp-1-medications-eating-disorders/ +date: 2026-01-01 +domain: health +secondary_domains: [] +format: article +status: unprocessed +priority: medium +tags: [glp-1, eating-disorders, clinical-guidance, screening, anad, professional-society, gastric-emptying, purging] +intake_tier: research-task +--- + +## Content + +ANAD (professional organization) guidance on GLP-1 medications and eating disorders. + +**Overall position:** "If you have a current or past eating disorder, please approach these medications with extreme caution and ensure you are working closely with a healthcare provider who understands eating disorders." + +**Evidence assessment:** "We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors." Long-term safety/effectiveness "especially for those with an eating disorder — remain unclear." + +**GI side effects and ED risk:** "Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance." + +**Poison control:** GLP-1 overdose calls have "tripled in recent years" — misuse pattern, not ED development. + +**Recommended screening BEFORE prescribing (no regulatory force):** +- ED history including type, severity, stage of recovery, coexisting medical/mental health issues, past treatments +- Screen for: current restrictive eating behaviors, active bingeing or purging, severe body image issues, unstable recovery + +**No quantitative incidence data provided** — "long-term research has yet to be done." + +**Multidisciplinary approach recommended:** Physician + therapist + dietitian all versed in both GLP-1s and eating disorders before prescribing. + +## Agent Notes + +**Why this matters:** ANAD is the authoritative professional society for eating disorders. Their guidance is the current clinical standard — and it's recommendation-only with zero regulatory force. The gap between recommended practice (tri-specialist team) and actual practice (no screening required, telehealth prescribing without any evaluation) is the operational measurement of the structural failure. + +**What surprised me:** ANAD's epistemic honesty: "We simply do not know" is a strong acknowledgment of the evidence gap. This is the national professional society saying they don't have enough evidence to make a clear recommendation — which itself tells you something about the state of the field. + +**What I expected but didn't find:** Any quantitative screening validation data. The SCOFF questionnaire and other screening tools exist but ANAD doesn't provide validation metrics here. + +**KB connections:** [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3% and no operational infrastructure connects screening to action]] — exact parallel: ED screening is recommended, no reimbursement, no operational pathway. + +**Extraction hints:** (1) ANAD recommendation vs. regulatory reality gap is itself a structural governance claim, (2) "Delayed gastric emptying can trigger or worsen purging in those already vulnerable" — confirms the "existing cycles" framing (not de novo), (3) Tri-specialist team recommendation as benchmark for what adequate clinical screening looks like. + +**Context:** ANAD is the primary US professional and advocacy organization for eating disorders. Guidance is current as of 2026. + +## Curator Notes + +PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] + +WHY ARCHIVED: ANAD guidance formalizes what "best practice" looks like (tri-specialist team + behavioral history) vs. what actually happens (no screening). The gap between recommended and actual practice is the operational measurement of the screening failure. + +EXTRACTION HINT: The ANAD guidance + regulatory gap can support a structural claim: GLP-1 prescribing without mandatory ED screening creates population-scale risk because recommended practice (tri-specialist evaluation) has no enforcement mechanism or reimbursement pathway.